NEW YORK (GenomeWeb News) – Phenomenome Discoveries has granted Polymedco Cancer Diagnostic Products a license to commercialize Phenomenome's mass spectrometry-based blood test for colorectal cancer in the US.

The test uses triple quadrupole mass spec technology to detect a deficiency in novel anti-cancer and anti-inflammatory metabolites in a blood sample, which Phenomenome said it has discovered occurs in nine out of 10 patients with colorectal cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.